Tofidence (tocilizumab-bavi)

aBL 761354

Tofidence (tocilizumab-bavi)

aBL 761354

U.S. License Holder:

Biogen / Bio-Thera

Date of License:

September-29-2023

Last Update:

Apr-15-2024

approved_indications FDA-Approved Indications

TOFIDENCE (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

Rheumatoid Arthritis (RA): Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs);

Polyarticular Juvenile Idiopathic Arthritis (PJIA): Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis;

Systemic Juvenile Idiopathic Arthritis (SJIA): Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:23-cv-11573 (D. Mass.)

U.S. Patent Nos.
7,332,289 (Method of Purifying Protein) 7,521,052 (Methods for Treating Interleukin-6 Related Diseases) 8,398,980 (Subtypes of Humanized Antibody Against Interleuken-6 Receptor) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,734,800 (Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 9,714,293 (Production of Proteins in Glutamine-Free Cell Culture Media) 9,902,777 (Methods for Producing Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells) 10,501,769 (Method for the Production of a Glycosylated Immunoglobulin) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate) 10,829,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,982,003 (Production of Proteins in Glutamine-Free Cell Culture Media) 11,021,728 (Method for the Production of a Glycosylated Immunoglobulin) 11,078,294 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 11,136,610 (Method for the Production of a Glycosylated Immunoglobulin) 11,377,678 (Method for the Production of a Glycosylated Immunoglobulin)

Plaintiffs
Genentech, Inc.; Chugai Pharmaceutical Co., Ltd.; Hoffmann-La Roche Inc.

Defendants
Biogen MA Inc.; Bio-Thera Solutions, Ltd.

Status
Stipulated Dismissal Due to Settlement

BPCIA
Y

Related News

Venable’s BiologicsHQ Monthly Injection – March 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
April 10, 2024
Spotlight On: Actemra® (tocilizumab) / Tofidence™ (tocilizumab-bavi) / Tyenne® (tocilizumab-aazg)
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
March 31, 2024
Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
March 31, 2024
Venable’s BiologicsHQ Monthly Injection – February 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
March 13, 2024
Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.
Robert S. Schwartz, Ph.D.
March 12, 2024
Chugai, Genentech, and Hoffmann-La Roche Dismiss Appeals of Actemra® Patent IPR Final Written Decisions
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 20, 2024
Venable’s BiologicsHQ Monthly Injection – January 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 13, 2024
Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47
Robert S. Schwartz
January 31, 2024
Venable’s BiologicsHQ Monthly Injection – December 2023
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
January 13, 2024
Venable’s BiologicsHQ Monthly Injection – September 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
October 16, 2023

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha